Scorecard: strongest in Access (3.5/5) and Patient Protection (3.4/5)
Semaglutide, sold under the brand names Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist
Once injected, a selective pulse travels through the brain, stimulating the anterior and hypothalamus-pituitary glands
This metabolic adaptation can make maintaining weight loss challenging
The oral GLP-1 market size in 2025 was US$ 6.81 billion, expected to grow to US$ 9.19 billion in 2026 and further to US$ 137.36 billion by 2035, backed by a robust CAGR of 35.05% between 2026 and 2035
An earlier study of 2,000 overweight adults compared people who took Semaglutide GLP-1 plus a diet and exercise program with people who made the same lifestyle changes but didnt take Semaglutide GLP-1